Valentina Pecoraro1,2, Rita Banzi2, Elisabetta Cariani1, Johanna Chester3, Erica Villa4, Roberto D'Amico5, Vittorio Bertele'2, Tommaso Trenti1. 1. Unit of Laboratory Medicine, Ospedale Civile Sant'Agostino Estense, Modena, Italy. 2. Center for Drug Regulatory Policies, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy. 3. Department of Surgery, Medical, Dentistry and Morphological Sciences, University of Modena e Reggio Emilia, Italy. 4. Department of Gastroenterology - AOU Modena, Modena, Italy. 5. Cochrane Italy - University of Modena and Reggio Emilia, Italy.
Abstract
BACKGROUND: New direct-acting antiviral agents (DAAs) approved for the treatment of patients infected by Hepatitis C virus (HCV) are well tolerated and increase sustained virological response (SVR) rate. We summarize current evidence on the efficacy and safety from comparative randomized controlled trials (RCTs) of DAAs. METHODS: We systematically searched MEDLINE, Embase, Scopus, CENTRAL, and Lilacs as well as a list of reference literature. We included RCTs comparing DAAs with placebo or active control and reporting response rates and adverse events according to antiviral regimens. Risk ratios (RRs) were pooled as appropriate. We assessed the risk of bias of included studies and graded the quality of evidence according to the GRADE method. RESULTS: We included 28 RCTs, enrolling more than 7000 patients. The quality of evidence was generally low. Twelve-week treatment with DAAs in naïve patients significantly increased SVR12 and SVR24 compared with placebo (RR 1.4, 95% CI 1.3-1.6; RR 1.5, 95% CI 1.4-1.6, respectively). This means that for every 1000 patients, 240 or 260 more patients experienced SVR12 or SVR24 if treated with any DAAs. We could not find RCTs assessing progression of liver disease or development of hepatocellular carcinoma. DAAs were not associated with higher incidence of serious adverse events or discontinuation due to adverse events. CONCLUSIONS: This systematic review confirms that new DAAs are more effective in inducing SVR than placebo. Outside clinical trials, in real word, HCV cure with DAA regimens occurs in less than 90% of patients, so further comparative evaluations are needed to establish their long-term effects.
BACKGROUND: New direct-acting antiviral agents (DAAs) approved for the treatment of patients infected by Hepatitis C virus (HCV) are well tolerated and increase sustained virological response (SVR) rate. We summarize current evidence on the efficacy and safety from comparative randomized controlled trials (RCTs) of DAAs. METHODS: We systematically searched MEDLINE, Embase, Scopus, CENTRAL, and Lilacs as well as a list of reference literature. We included RCTs comparing DAAs with placebo or active control and reporting response rates and adverse events according to antiviral regimens. Risk ratios (RRs) were pooled as appropriate. We assessed the risk of bias of included studies and graded the quality of evidence according to the GRADE method. RESULTS: We included 28 RCTs, enrolling more than 7000 patients. The quality of evidence was generally low. Twelve-week treatment with DAAs in naïve patients significantly increased SVR12 and SVR24 compared with placebo (RR 1.4, 95% CI 1.3-1.6; RR 1.5, 95% CI 1.4-1.6, respectively). This means that for every 1000 patients, 240 or 260 more patients experienced SVR12 or SVR24 if treated with any DAAs. We could not find RCTs assessing progression of liver disease or development of hepatocellular carcinoma. DAAs were not associated with higher incidence of serious adverse events or discontinuation due to adverse events. CONCLUSIONS: This systematic review confirms that new DAAs are more effective in inducing SVR than placebo. Outside clinical trials, in real word, HCV cure with DAA regimens occurs in less than 90% of patients, so further comparative evaluations are needed to establish their long-term effects.
Authors: J P Ioannidis; A B Haidich; M Pappa; N Pantazis; S I Kokori; M G Tektonidou; D G Contopoulos-Ioannidis; J Lau Journal: JAMA Date: 2001-08-15 Impact factor: 56.272
Authors: Gordon Guyatt; Andrew D Oxman; Elie A Akl; Regina Kunz; Gunn Vist; Jan Brozek; Susan Norris; Yngve Falck-Ytter; Paul Glasziou; Hans DeBeer; Roman Jaeschke; David Rind; Joerg Meerpohl; Philipp Dahm; Holger J Schünemann Journal: J Clin Epidemiol Date: 2010-12-31 Impact factor: 6.437
Authors: Stanislas Pol; Reem H Ghalib; Vinod K Rustgi; Claudia Martorell; Greg T Everson; Harvey A Tatum; Christophe Hézode; Joseph K Lim; Jean-Pierre Bronowicki; Gary A Abrams; Norbert Bräu; David W Morris; Paul J Thuluvath; Robert W Reindollar; Philip D Yin; Ulysses Diva; Robert Hindes; Fiona McPhee; Dennis Hernandez; Megan Wind-Rotolo; Eric A Hughes; Steven Schnittman Journal: Lancet Infect Dis Date: 2012-06-18 Impact factor: 25.071
Authors: Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher Journal: BMJ Date: 2009-07-21
Authors: Mark S Sulkowski; Tarik Asselah; Jacob Lalezari; Peter Ferenci; Hugo Fainboim; Barbara Leggett; Fernando Bessone; Stefan Mauss; Jeong Heo; Yakov Datsenko; Jerry O Stern; George Kukolj; Joseph Scherer; Gerhard Nehmiz; Gerhard G Steinmann; Wulf O Böcher Journal: Hepatology Date: 2013-06 Impact factor: 17.425
Authors: Iman Ibrahim Salama; Hala M Raslan; Ghada A Abdel-Latif; Somaia I Salama; Samia M Sami; Fatma A Shaaban; Aida M Abdelmohsen; Walaa A Fouad Journal: World J Hepatol Date: 2022-06-27
Authors: Francisco J Zapatero-Belinchón; Rina Ötjengerdes; Julie Sheldon; Benjamin Schulte; Belén Carriquí-Madroñal; Graham Brogden; Laura M Arroyo-Fernández; Florian W R Vondran; Benjamin Maasoumy; Thomas von Hahn; Gisa Gerold Journal: Cells Date: 2021-06-29 Impact factor: 6.600